Thursday, November 16, 2017
8:00 a.m. to 8:30 a.m. EST - Breakfast
8:30 a.m. to 10:30 a.m. EST - Meeting
The meeting will feature presentations by:
Troy Wilson, Ph.D., J.D., President & CEO, Kura Oncology, Inc.
Antonio Gualberto, M.D., Ph.,D., Chief Medical Officer, Kura Oncology, Inc.
Kura’s management team will provide an in-depth overview of the company’s ongoing clinical development program with tipifarnib, a novel, oral therapy for HRAS mutant head and neck squamous cell carcinoma (HNSCC). The company recently announced positive results in its Phase 2 study in HRAS mutant HNSCC and plans to initiate a pivotal trial in 2018.